Sign In
Buy JAZZ
$230.93
+4.81 (+2.13%)
At Close: Jun 03, 2026
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
10:06pm, Thursday, 28'th Dec 2023
With the Federal Reserve previously engaged in a bitter – and seemingly, at times desperate – struggle against blisteringly hot inflation, the narrative for growth stocks to buy now frankly didn't
20 midcap stocks with 2024 upside ranging up to 62%, according to analysts
01:02pm, Tuesday, 26'th Dec 2023
When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After
Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals
01:32pm, Friday, 22'nd Dec 2023
After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.
Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial
05:30pm, Thursday, 21'st Dec 2023
Jazz Pharmaceuticals said on Thursday its post-traumatic stress disorder (PTSD) drug failed to meet the main goal in a mid-stage study.
Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:15pm, Wednesday, 20'th Dec 2023
DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Confer
3 No-Brainer Stocks to Buy With $500 Right Now
05:21am, Wednesday, 20'th Dec 2023
Some of Wall Street's major stock indexes remain below their all-time highs, which means bargains can still be found. Most online brokerages have done away with commission fees and minimum-deposit req
Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?
12:48pm, Friday, 08'th Dec 2023
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Data from nine abstracts to be presented, including real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsies Presentations include data on U.S. caregiver-reported seizu
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
07:45am, Thursday, 30'th Nov 2023
New trial results of investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer Strong presence at ASH includes 11 presentations spanning Jazz's portfol
3 Top-Rated Biotech Stocks That Analysts Are Loving Now
08:48am, Tuesday, 28'th Nov 2023
Investing in biotech stocks is not for risk-averse investors. However, if you're an investor who is serious about generating outsized gains, it's a sector that you can't overlook.
3 No-Brainer Stocks to Buy With $200 Right Now
05:21am, Wednesday, 15'th Nov 2023
The Dow, S&P 500, and Nasdaq Composite have teetered between bull and bear markets for much of the past four years. Online brokerages have made it easier than ever to grow your wealth on Wall Street.
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
03:03pm, Thursday, 09'th Nov 2023
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
Fleetcor Technologies, Inc. (FLT) Q3 2023 Earnings Call Transcript
11:34pm, Wednesday, 08'th Nov 2023
Fleetcor Technologies, Inc. (FLT) Q3 2023 Earnings Conference Call November 8, 2023 5:30 PM ET Company Participants James Eglseder - Head, IR Ronald Clarke - Chairman, President & CEO Thomas Panther -
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics
08:17pm, Wednesday, 08'th Nov 2023
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street
Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics
02:17pm, Tuesday, 07'th Nov 2023
Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
